Protecting the World from Pertussis and Other Emerging Diseases
BioNet is a leading developer and manufacturer of vaccines, specializing in recombinant and mRNA-based solutions targeting respiratory diseases and other global public health challenges. With a proven track record in research, development, and biomanufacturing, BioNet has successfully advanced proprietary recombinant pertussis vaccines from early-stage innovation to licensure.
BioNet Receives Positive CHMP Opinion from EMA for VacPertagen, a Recombinant Vaccine against Pertussis
Lyon, November 18, 2025: BioNet, a biotechnology company focused on next-generation vaccines, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a marketing authorisation in the European Union for VacPertagen, a standalone acellular pertussis vaccine.
CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product VacPertagen, a vaccine intended for prophylaxis against pertussis.
